摘要
目的对依达拉奉联合灯盏花素注射液治疗急性脑梗死的临床疗效与安全性进行系统评价。方法检索国内外多个数据库中已经公开发表的关于依达拉奉联合灯盏花素治疗急性脑梗死的临床随机对照试验的相关文献,依据纳入、排除筛选数据应用Review Manager5.3做Meta分析。结果共纳入10个随机对照试验,分析显示,对于急性脑梗死,依达拉奉联合灯盏花素注射液治疗的神经功能缺损临床疗效的比值比(OR)合并值为3.83(95%可信区间为2.60~5.64)。神经功能缺损评分疗效标准化均数差(SMD)合并值为-6.33(95%可信区间为-9.80^-2.86)。结论对于急性脑梗死,依达拉奉联合灯盏花素注射液治疗有确切疗效,且安全、不良反应较少,但由于所选样本质量偏低,尚需进一步进行严格的、多中心的随机双盲对照试验来验证,以便提供更有效的说服力。
Objective On the basis of strict quality evaluation,clinical curative effect and the safety of edaravone combined with Breviscapine injection for the treatment of acute cerebral infarction（ACI） were made a system evaluation. Methods The randaomized controlled clinical trials of edaravone combined with Breviscapine Injection for the treatment of ACI from 1989-2014 were searched by computed-based on line search,and the data was statistically analyzed by Review Manager 5.3. Results The results showed that there were 10 literatures which incorporated by Meta-analysis. The analysis showed that the OR（95% CI） was3.83（2. 60~5. 64）,SMD（95%CI）was-6. 33（-9. 80^-2. 86）. Conclusion The edaravone combined with Breviscapine injection has confirmative curative effect on the treatment of ACI. It is safe and has less adverse effect. However,there still need some strict and multicentric randomized double-mind control tests to be carried out,in order to provide more effective and convinced evidence.
出处
《云南中医学院学报》
2016年第2期73-77,共5页
Journal of Yunnan University of Traditional Chinese Medicine
关键词
依达拉奉
灯盏花素
急性脑梗死
META分析
Edaravone
Breviscapine injection
acute cerebral infarction
Meta analysis
